Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week Open-label Maintenance Study of Aripiprazole IM Depot in Schizophrenia
2008-002699-83Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maintenance of stability at 52 weeks and Safety and tolerability. Started Nov 2008; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2008-002699-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002699-83.